Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270658 | PMC |
| http://dx.doi.org/10.18632/aging.101153 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer.
Biomedicines
July 2024
Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, D830, Boston, MA 02215, USA.
Patients with pancreatic neuroendocrine tumors (pNETs) have limited access to effective targeted agents and invariably succumb to progressive disease. MUC1-C is a druggable oncogenic protein linked to driving pan-cancers. There is no known involvement of MUC1-C in pNET progression.
View Article and Find Full Text PDFMUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progression.
Oncogene
July 2024
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
The MUC1 gene evolved in mammals for adaptation of barrier tissues in response to infections and damage. Paraspeckles are nuclear bodies formed on the NEAT1 lncRNA in response to loss of homeostasis. There is no known intersection of MUC1 with NEAT1 or paraspeckles.
View Article and Find Full Text PDFXIST and MUC1-C form an auto-regulatory pathway in driving cancer progression.
Cell Death Dis
May 2024
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
The long non-coding RNA X-inactive specific transcript (lncRNA XIST) and MUC1 gene are dysregulated in chronic inflammation and cancer; however, there is no known interaction of their functions. The present studies demonstrate that MUC1-C regulates XIST lncRNA levels by suppressing the RBM15/B, WTAP and METTL3/14 components of the m6A methylation complex that associate with XIST A repeats. MUC1-C also suppresses the YTHDF2-CNOT1 deadenylase complex that recognizes m6A sites and contributes to XIST decay with increases in XIST stability and expression.
View Article and Find Full Text PDFIdentification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas.
Cancer Res Commun
May 2024
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Unlabelled: The MUC1-C protein is aberrantly expressed in adenocarcinomas of epithelial barrier tissues and contributes to their progression. Less is known about involvement of MUC1-C in the pathogenesis of squamous cell carcinomas (SCC). Here, we report that the MUC1 gene is upregulated in advanced head and neck SCCs (HNSCC).
View Article and Find Full Text PDFMUC1-C intersects chronic inflammation with epigenetic reprogramming by regulating the set1a compass complex in cancer progression.
Commun Biol
October 2023
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Chronic inflammation promotes epigenetic reprogramming in cancer progression by pathways that remain unclear. The oncogenic MUC1-C protein is activated by the inflammatory NF-κB pathway in cancer cells. There is no known involvement of MUC1-C in regulation of the COMPASS family of H3K4 methyltransferases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!